Atara Biotherapeutics

Biotechnology

US Equity Research
22 October 2015

BUY
unchanged

PRICE TARGET US$80.00
unchanged
Price (21-Oct) US$24.99
Ticker ATRA-NASDAQ

52-Week Range (US$):	12.61 - 65.56
Avg Daily Vol (000s) :	0.3
Market Cap (US$M):	1,214
Shares Out. (M) :	24.2

FYE Dec	2014A	2015E	2016E
Revenue (US$M)	0	0	0
EPS Adj&Dil (US$)	(8.50)	(2.03)	(4.65)

Quarterly Revenue	Q1	Q2	Q3	Q4
2014A	0	0	0	0
2015E	0A	0A	0	0
2016E	0	0	0	0

Quarterly EPS Adj&Dil	Q1	Q2	Q3	Q4
2014A	0.00	0.00	(4.20)	0.00
2015E	(0.41)A	(0.25)A	(0.69)	(0.65)
2016E	(0.88)	(0.96)	(1.41)	(1.35)

John Newman, PhD | Canaccord Genuity Inc. (US) | JNewman@canaccordgenuity.com | 212.389.8042

Company Update

Positive analyst day update, top-line PINTA data expected December 2015

12-week PINTA data in December, secondary endpoints key

We expect positive top-line data for PINTA-745 in Protein Energy Wasting (PEW) in dialysis patients during December 2015, including positive data for secondary endpoints addressing quality of life. Importantly, the treatment period is 3x longer than the positive Phase 1 proof-of-concept study in Prostate Cancer, and dosing regimens will give higher drug exposure, suggesting a higher probability of success. We look for positive data on secondary endpoints at 12 weeks, including: (1) six-minute walk test and stair climb power test; (2) Hemoglobin A1C, Insulin resistance, use of diabetes meds; (3) Effect on use of ESAs; and (4) inflammation, measured by TNF-a, IL-6, and C-reactive protein.

Pivotal EBV T-cell studies start 2016/2017, favorable endpoints

Atara will begin Phase 3 studies for its EBV T-cell programs in lymphoproliferative and Solid Organ Transplant in 2016, with a single-arm study slated for EBV after Stem Cell Transplant in Lymphoproliferative disorder. Pivotal studies will follow multicenter trials with MSK T-cells, and trasition to Atara product in Phase 3. We view Best Overall Response Rate for EBV T-cell in lymphoproliferative disorder as a very favorable primary endpoint given the 65% response rate, and 64% Overall Survival seen at ASCO in 2015. Also, Event Free Survival is a favorable primary endpoint for EBV in Solid Organ Transplant given the ~58% Overall Survival also seen at ASCO in 2015, which we believe suggests much better outcomes vs. the control chemotherapy arm.

Multiple Sclerosis EBV indication intriguing

Atara's T-cell technology may be applicable in Multiple Sclerosis, given the high percentage of patients infected with Epstein Barr Virus, an intriguing long-term opportunity. Although early, Atara's new partner QIMR reviewed data for autologous EBV-specific T-cell therapy in an MS patient suggesting interesting results. This indication will of course require substantial additional investigation, but illustrates the broad potential for Atara's allogeneic T-cell platform, in our view.

QIMR partnership adds deep antigen expertise, complimentary

Atara's QIMR partnership gives deep expertise in antigens for EBV, and could speed development of various programs. Importantly, Atara was introduced to QIMR by Sloan Kettering, and therefore we do not view the new partnership as competitive. The lead investigator at Sloan Kettering, Dr. Richard O'Reilly, noted the valuable expertise that QIMR provides with regard to epitope specificity.

For important information, please see the Important Disclosures beginning on page 12 of this document.

Expect positive 12-week PINTA-745 data in December, including secondary functional endpoints

We expect positive top-line data for PINTA-745 in dialysis patients with Protein Energy Wasting (PEW) disease in December, and believe secondary endpoints will show a positive effect. Importantly, the dosing period for Atara's study is 3x longer than the prior positive Phase 1 trial in Prostate cancer, and higher drug levels will be achieved, both of which increase the chance of success in our view. Peak effect for PINTA-745 in the Phase 1 study in prostate cancer was seen at 2 months, after only 4 weeks of dosing (Figure 1 and 2), whereas Atara's current Phase 2 study will report data at 12 weeks, after 12 weeks of dosing.

Figure 1: PINTA-745 Phase 1 Prostate Cancer Study

Table 4. Percentage Change From Baseline for Lean Body Mass, Whole-Body Fat, and Lower-Extremity Muscle Size

	Lean Body Mass[a]	Whole-Body Fat[b,c]	Lower-extremity Muscle Size[d]
End point: percentage change from baseline to day 29[e]			
AMG 745	1.5% (0.5%)	−1.7% (0.7%)	1.2% (0.7%)
Placebo	−0.7% (0.5%)	0.8% (0.7%)	−0.7% (0.7%)
Between-group difference	2.2% (0.8%)	−2.5% (1.0%)	1.8% (1.0%)
P value	.008	.021	.065
End point: percentage change from baseline to follow-up day 58[e]			
AMG 745	1.9% (0.5%)	−1.5% (1.1%)	2.7% (0.7%)
Placebo	0.2% (0.5%)	0.5% (1.1%)	−0.1% (0.7%)
Between-group difference	1.7% (0.7%)	−2.0% (1.5%)	2.8% (1.0%)
P value	.023	.183	.007

[a] As assessed by DXA scan.

[b] Prespecified exploratory analysis.

[c] As assessed by CT scan.

[d] Values are least squares mean (SE), except *P* values.

[e] Lean body mass (minus the head), as assessed by DXA scan.

Source: Padhi et al, J Clin Endocrinol Metab, October 2014, 99(10):E1967-E1975

Figure 2: PINTA-745 Phase 1 Prostate Cancer study, lean muscle mass



Figure 2. A, Lean body mass and percentage change from baseline in total lean body mass determined by blinded central review of DXA data in men with prostate cancer on ADT receiving AMG 745 or placebo. The bottom and top of the boxes represent the first and third quartiles, and the horizontal band inside the box indicates the median value. The ends of the whiskers indicate the minimum and maximum data in the range of observations. Black color represents the placebo group, whereas red color indicates the AMG 745-treated group. EOS represents day 29, and FUP represents 1 month after day 29. *P* values are based on ANOVA comparison of the placebo, and AMG 745 3 mg/kg treatment groups are indicated. B, body fat and ercentage change from baseline in total body fat determined by blinded central review of DXA data in men with prostate cancer on ADT receiving AMG 745 or placebo. The bottom and top of the boxes represent the first and third quartiles, and the horizontal band inside the box indicates the median value. The ends of the whiskers indicate the minimum and maximum data in the range of observations. Black color represents the placebo group, whereas the red color indicates the AMG 745-treated group. EOS represents day 29, and FUP represents 1 month after day 29. *P* values are based on an ANOVA comparison of the placebo, and AMG 745 3 mg/kg treatment groups are indicated. C, Lower extremity muscle size and percentage change from baseline in lower extremity muscle size determined by blinded central review of CT data in men with prostate cancer on ADT receiving AMG 745 or placebo. The bottom and top of the boxes represent the first and third quartiles, and the horizontal band inside the box indicates the median value. The ends of the whiskers indicate the minimum and maximum data in the range of observations. Black color represents the placebo group, whereas the red color indicates the AMG 745-treated group. EOS represents day 29, and FUP represents 1 month after day 29. *P* values are based on ANOVA comparison of the placebo and AMG 745 3 mg/kg treatment groups are indicated. FUP, follow-up period.

Source: Padhi et al, J Clin Endocrinol Metab, October 2014, 99(10):E1967-E1975

As mentioned above, the Phase 2 study for PINTA-745 in Protein Energy Wasting in dialysis patients involves 12 weeks of dosing. Patients will be randomized 3:1 to PINTA-745 vs placebo and dosed via IV once weekly for four weeks. Patients on active drug will receive one of three doses: 3 mg/kg for 12 weeks, 3 mg/kg for 3 weeks, followed by 1 mg/kg for 9 weeks, or 6 mg/kg for 3 weeks, followed by 2 mg/kg for 9 weeks. Placebo doses will also match the three dosing schedules for active drug (Figure 3).

Figure 3: PINTA-745 trial - Protein Energy wasting - dosing

Arms	Assigned Interventions
Experimental: **PINTA 745**	Drug: **PINTA 745** **PINTA 745** will be administered once weekly by IV infusion. Cohort dose schedules: 3mg/kg weekly for 12 weeks 3mg/kg for 3 weeks, followed by 1mg/kg for 9 weeks 6mg/kg for 3 weeks, followed by 2mg/kg for 9 weeks
Placebo Comparator: Placebo	Drug: Placebo Placebo will be administered once weekly by IV infusion. Cohort dose schedules: 3mg/kg weekly for 12 weeks 3mg/kg for 3 weeks, followed by 1mg/kg for 9 weeks 6mg/kg for 3 weeks, followed by 2mg/kg for 9 weeks

Source: www.clinicaltrials.gov

Figure 4: PINTA-745 Phase 2 study



Source: Company Reports, Canaccord Genuity estimates

Secondary endpoints in focus for PINTA-745

We expect top-line data for PINTA-745 to show positive results for secondary endpoints describing physical function, and other important measures. Importantly, the study is not powered to show statistically significant differences for secondary endpoints, but we expect positive trends. Most important among the secondary endpoints, in our view, is the 6-min walk test and stair power climb test, but encouraging signals for metabolic endpoints would also be a meaningful plus (Figure 5).

Figure 5: PINTA-75 Phase 2 secondary endpoints



Source: Company Reports, Canaccord Genuity estimates

Figure 6: Atara catalysts

Event	Timing	Description	Effect	Importance	Notes
Data	Dec-15	PINTA-745	↑	Critical	12-week top-line data Phase 2 in PEW in dialysis
Data	YE15	MSK T-cell programs	↑	High	Additional data
Data	1Q16	PINTA-745	↑	Critical	20-week data Phase 2 in PEW in dialysis
Data	1H16	STM-434	↑	High	Results of Phase 1 in ovarian and solid tumors
Clinical	1H16	Initiate first EBV-PTLD pilot study	↑	High	
Clinical	2016	ATA 842	↑	Moderate	File IND, initiate firat in human study
Clinical	2016	Two EBV pivotal studies	↑	High	Initiate two Phase 3 studies EBV, HCT, SOT

Source: Company Reports, Canaccord Genuity estimates

Figure 7: Atara valuation

Product	Peak Sales / Royalty ($MM)	Peak Year	NPV at launch ($MM)	Probability Adjustment	Current Value ($MM)	EV/S multiple	Value / Share NPV	Value / Share EV / S	Average NPV, EV / S
PINTA-745									
US	1,575	2025	3,470	40%	576	5.5	$24	$41	$32
Ex-US (royalty)	127	2026	340	40%	73	5.5	$3	$3	$3
STM-434									
US	185	2025	269	30%	(1)	5.5	($0)	$4	$2
Ex-US (royalty)	11	2026	97	30%	16	5.5	$1	$0	$0
EBV-CTL									
Hematopoetic Stem Cell Transplant									
US	164	2025	622	50%	239	5.5	$10	$6	$8
Ex-US (royalty)	42	2025	192	50%	66	5.5	$3	$1	$2
Solid Organ Transplant									
US	187	2023	1,206	50%	410	5.5	$17	$7	$12
Ex-US (royalty)	23	2022	301	50%	103	5.5	$4	$1	$3
CMV-CTL									
US	123	2025	227	35%	38	5.5	$2	$3	$2
Ex-US (royalty)	36	2026	99	35%	18	5.5	$1	$1	$1
Equity Value							**$64**	**$66**	$65
Total Equity Value							$64	$66	$65
Net Cash							$15	$15	$15
Value per share							**$79**	**$82**	**$80**
Shares Outstanding (MM)							24		

Risk-Free Rate	2%
Beta	1.3
Risk Premium	9%
Discount Rate	13%

Source: Company Reports, Canaccord Genuity estimates

Figure 8: Atara - Income Statement

Atara Biotherapeutics

($000's) [FY - DEC]	2014A	1Q15A	2Q15A	3Q15E	4Q15E	2015E	2016E	2017E	2018E	2019E	2020E
Revenue:											
PINTA-745 - US									-	-	246,790
PINTA-745 - Ex-US royalty									-	-	-
STM-434 - US									-	18,800	57,810
STM-434 - Ex-US royalty									-	-	1,210
EBV-CTL - US											
HSCT									32,345	62,973	114,467
Solid Organ Transplant									20,166	62,321	106,998
EBV-CTL - Ex-US royalty											
HSCT									9,547	18,621	32,893
Solid Organ Transplant									3,208	9,673	16,202
CMV-CTL - US									-	17,088	35,209
CMV-CTL - Ex-US royalty									-	-	-
Total revenue	**-**	-	-	-	-	**-**	**-**	**-**	**65,267**	**189,477**	**611,580**
COGS	-	-	-	-	-	-	-	-	10,502	32,237	112,255
Gross profit	-	-	-	-	-	-	-	-	54,765	157,241	499,325
Operating expenses:											
Research and development	**15,446**	**5,767**	**7,007**	**12,771**	**12,198**	**37,743**	**124,300**	**144,750**	**146,982**	**150,306**	**150,280**
PINTA745	2,311	1,477	1,433	1,500	200	4,610	50,000	53,333	56,000	58,800	61,740
STM 434	4,389	664	628	1,250	1,250	3,792	13,333	16,667	17,500	12,250	8,575
ATA 842	624	982	1,825	1,000	1,000	4,807	4,000	7,333	13,333	35,000	36,750
T-cell therapy Programs (Option to license T-cell therapies	2,000	122	4,587	5,380	5,379	15,468	38,617	48,150	39,918	23,014	20,911
EBV-CTL				3,267	3,267	6,533	25,067	30,080	15,040	7,520	6,768
CMV-CTL				1,513	1,513	3,025	12,050	16,870	23,618	14,171	12,754
WT1-CTL				601	600	1,201	1,500	1,200	1,260	1,323	1,389
Other R&D											
Employee and overhead costs	6,122	2,522	3,034	3,641	4,369	13,566	18,350	19,267	20,230	21,242	22,304
Research and development costs paid to Amgen	(1,066)					0					
In-process R&D acquired from Amgen	-					0					
In-process R&D acquired from MSK			(4,500)								
Selling, General and Administrative	12,710	3,544	3,601	4,500	4,500	16,145	17,044	18,748	29,998	52,498	86,248
Total operating expenses	42,536	9,311	6,108	17,271	16,698	49,388	141,344	163,499	176,980	202,804	236,528
Operating Profit	**(42,536)**	**(9,311)**	**(6,108)**	**(17,271)**	**(16,698)**	**(49,388)**	**(141,344)**	**(163,499)**	**(122,215)**	**(45,564)**	**262,796**
Interest expense / income (net)	125	153	163			316					
Provision (benefit) for income taxes	25	(2)				(2)					
Unrealized losses on investments	25	82				82					
Other comprehensive loss			(48)								
Income tax benefit (expense)											
Net income	**(42,361)**	**(9,078)**	**(5,993)**	**(17,271)**	**(16,698)**	**(49,040)**	**(141,344)**	**(163,499)**	**(122,215)**	**(45,564)**	**262,796**
GAAP EPS	**($8.50)**	**($0.41)**	**($0.25)**	**($0.69)**	**($0.65)**	**($2.03)**	**($4.65)**	**($4.90)**	**($3.38)**	**($1.20)**	**$6.60**
Shares Diluted	4,986	21,918	24,224	24,951	25,699	24,198	30,423	33,373	36,113	37,919	39,815

Source: Company Reports, Canaccord Genuity estimates

Figure 9: Atara - Balance Sheet

Atara Balance Sheet	2014A	1Q15A	2Q15A	3Q15E	4Q15E	2015E	2016E	2017E	2018E	2019E	2020E
Assets											
Cash and cash equivalents	21,897	71,329	26,190	262,609	251,614	251,614	216,476	185,120	171,176	160,129	458,695
Short-term available-for-sale investments	82,219	95,367	128,841	169,157	177,615	177,615	215,892	241,799	263,561	284,646	301,725
Prepaid expenses and other current assets	1,910	2,995	5,603	5,883	6,177	6,177	7,509	8,410	9,166	9,900	10,494
Total Current Assets	**106,026**	**169,691**	**160,634**	437,649	435,406	435,406	439,877	435,329	443,903	454,674	770,914
Property/Equipment, Net	48	47	42	44	46	46	56	63	69	74	79
Other assets	48	79	426	-	-	-	-	-	-	-	-
Total Assets	**106,122**	**169,817**	**161,102**	**875,342**	**870,858**	870,858	879,810	870,720	887,875	909,423	1,541,906
Liabilities											
Accounts payable	440	794	1,703	1,788	1,878	1,878	2,282	2,556	2,786	3,009	3,190
Accrued compensation	1,225	522	924	970	1,019	1,019	1,238	1,387	1,512	1,633	1,731
Series A-1 convertible preferred shares issued to Ar	1			-	-		-	-	-	-	-
Income tax payable		1	1	1	1	1	1	2	2	2	2
License fee payable to MSK		-	4,500	4,725	4,961	4,961	6,030	6,754	7,362	7,951	8,428
Other accrued liabilities	1,058	2,197	4,516	4,742	4,979	4,979	6,052	6,778	7,388	7,979	8,458
Total Current Liabilities	**2,724**	**3,514**	**11,644**	**12,226**	**12,838**	12,838	15,604	17,477	19,049	20,573	21,808
Other long-term liabilities	216	209	203	213	224	224	272	305	332	359	380
Total Liabilities	**2,940**	**3,723**	**11,847**	**12,439**	**13,061**	**13,061**	**15,876**	**17,781**	**19,382**	**20,932**	**22,188**
Preferred stock	-	-	-								
Common stock	2	2	2								
Additional paid-in capital	144,169	216,159	214,313								
Accumulated other comprehensive income	(100)	(18)	(66)								
Accumulated Deficit	(40,889)	(50,049)	(64,994)								
Total Equity	**103,182**	**166,094**	**149,255**	**862,902**	**857,797**	**857,797**	**863,934**	**852,939**	**868,493**	**888,491**	**1,519,718**
Total Liabilities & Shareholders' Equity	**106,122**	**169,817**	**161,102**	**875,342**	**870,858**	**870,858**	**879,810**	**870,720**	**887,875**	**909,423**	**1,541,906**

Source: Company Reports, Canaccord Genuity estimates

Figure 10: Atara - Statement of Cash Flows

($000's) [FY- JUN]	2014A	1Q15A	2Q15A	3Q15E	4Q15E	2015E	2016E	2017E	2018E	2019E	2020E
Atara statement of cash flows											
Net Income (Loss)		(9,160)	(14,945)	(17,271)	(16,698)	(58,074)	(141,344)	(163,499)	(122,215)	(45,564)	262,796
Adjustments to reconcile net loss to net cash used in operating activities:											
Non-cash research and development expenses		-	-			-	-				
Depreciation expense		6	5	5	5	21	84	84	84	84	84
Investment premium amortization, net		358	522	522	522	1,924	7,696	7,696	7,696	7,696	7,696
Stock-based compensation expense		2,483	2,570	3,598	5,037	13,688	22,797	23,936	25,133	26,390	27,709
Interest accrued on notes receivable from stockholder		-	-			-	-				
Changes in operating assets and liabilities:						-	-				
Other assets		(31)	7			(24)	-				
Prepaid expenses and other current assets		(1,081)	(2,233)	(280)	(294)	(3,888)	(1,331)	(901)	(757)	(733)	(594)
Accounts payable		354	808			1,162	-				
Income tax payable		-	-			-	-				
Other accrued liabilities		1,139	2,108	226	237	3,710	1,073	726	610	591	479
License fee payable to MSK			4,500	225	236	4,961	1,069	724	608	589	477
Accrued compensation		(703)	402	(46)	(49)	(396)	(220)	(149)	(125)	(121)	(98)
Other long-term liabilities		13	(40)	10	11	(6)	48	**33**	**27**	**27**	**22**
Cash from Operating Activities		(6,622)	(6,296)	(13,011)	(10,993)	(36,922)	(110,128)	(131,350)	(88,939)	(11,042)	298,571
Purchase of short-term investments		(54,796)	(56,529)	-	-	(111,325)	-	-	-	-	-
Maturities of short-term investments		41,368	22,142	-	-	63,510	-	-	-	-	-
Purchase of property and equipment		(5)	-	(2)	(2)	(9)	(10)	(7)	(6)	(5)	(4)
Cash from Investing Activities		(13,433)	(34,387)	(2)	(2)	(47,824)	(10)	(7)	(6)	(5)	(4)
Repayment of notes receivable from stockholder		-	-			-	-				
Proceeds from sale of common stock, net of offering costs		69,487	-	200,000		269,487	75,000	100,000	75,000		
Taxes paid related to net share settlement of restricted stock units			(4,468)			(4,468)	-				
Proceeds from sale of convertible preferred stock		-	-			-	-				
Offering costs incurred in connection with sale of convertible preferred stock		-	-			-	-				
Offering costs incurred in anticipation of initial public filing		-	(42)			(42)	-				
Cash from Financing Activities		69,487	(4,510)	200,000	-	264,977	75,000	100,000	75,000	-	-
Net Change in Cash		49,432	4,293	186,987	(10,995)	229,717	(35,137)	(31,356)	(13,944)	(11,047)	298,567
Net Cash - Beginning Balance		21,897	71,329	75,622	262,609	71,329	309,183	216,476	185,120	171,176	160,129
Net Cash - Ending Balance		71,329	75,622	262,609	251,614	251,614	216,476	185,120	171,176	160,129	458,695

Source: Company Reports, Canaccord Genuity estimates

Appendix: Important Disclosures

Analyst Certification

Each authoring analyst of Canaccord Genuity whose name appears on the front page of this research hereby certifies that (i) the recommendations and opinions expressed in this research accurately reflect the authoring analyst's personal, independent and objective views about any and all of the designated investments or relevant issuers discussed herein that are within such authoring analyst's coverage universe and (ii) no part of the authoring analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by the authoring analyst in the research.

Analysts employed outside the US are not registered as research analysts with FINRA. These analysts may not be associated persons of Canaccord Genuity Inc. and therefore may not be subject to the NASD Rule 2711 and NYSE Rule 472 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

Target Price / Valuation Methodology:

Atara Biotherapeutics - ATRA

Our $80 price target for Atara is based on an average of two valuation models. We utilize a sum-of-the-parts probability-adjusted NPV model with a 13% discount rate, and probability-adjust each indication between 30% and 50% based on the product and stage of development. Our effective discount rate is ~23% when taking into account probability adjustments. We also utilize a 5.5x multiple, based on a historical analysis of biotechnology companies, for an EV/S model.

Risks to achieving Target Price / Valuation:

Atara Biotherapeutics - ATRA

Clinical risks: Atara Biotherapeutics is a clinical-stage biotechnology company and we see various clinical regulatory, competitive, and safety risks to our rating and price target. Importantly, Atara's T-cell programs are not approved by FDA and could generate negative clinical data. The PINTA-745 program may also generate negative efficacy and/or safety data in the current Phase 1/2 trial and/or in subsequent trials. The STM-434 program is early in development, and has not yet generated data in humans.

Manufacturing risks: Atara's T-cell programs carry higher manufacturing risk versus biologic antibodies and small molecules since they are generated from human samples in a complex manner. Atara could experience challenges in transferring manufacturing from MSK to a larger, commercial-scale facility, and the FDA may also request stringent validation for the transfer. Although less complex, the PINTA-745 and STM-434 programs also carry manufacturing risk, as they are biologic products.

Regulatory risks: Atara's programs are not approved by FDA and could carry higher regulatory risk than expected.

Commercial and competitive risks: Atara may secure FDA approval for one or more products in its pipeline, but may generate revenues below our estimates. Also, the company may be unable to secure favorable reimbursement due to growing pressure on drug costs in the US. The biotechnology sector is highly competitive, and current and/or future competitors may emerge for Atara's products that could result in materially lower revenues than projected.

Financial risks: Atara has no revenues, and may not have revenues for several years, during which time the company is likely to need to raise significant additional capital, resulting in potential dilution for shareholders.

Intellectual property risks: Atara's pipeline consists entirely of biologic assets, increasing the barriers to entry from an intellectual property standpoint, but other entities or companies may challenge the company's intellectual property portfolio.

Distribution of Ratings:

Global Stock Ratings (as of 10/22/15)

Rating	Coverage Universe		IB Clients
	#	%	%
Buy	613	62.81%	31.97%
Hold	279	28.59%	11.83%
Sell	26	2.66%	3.85%
Speculative Buy	58	5.94%	58.62%
	976*	100.0%	

*Total includes stocks that are Under Review

Canaccord Genuity Ratings System

BUY: The stock is expected to generate risk-adjusted returns of over 10% during the next 12 months.

HOLD: The stock is expected to generate risk-adjusted returns of 0-10% during the next 12 months.

SELL: The stock is expected to generate negative risk-adjusted returns during the next 12 months.

NOT RATED: Canaccord Genuity does not provide research coverage of the relevant issuer.

"Risk-adjusted return" refers to the expected return in relation to the amount of risk associated with the designated investment or the relevant issuer.

Risk Qualifier

SPECULATIVE: Stocks bear significantly higher risk that typically cannot be valued by normal fundamental criteria. Investments in the stock may result in material loss.

Canaccord Genuity Company-Specific Disclosures (as of date of this publication)

Atara Biotherapeutics currently is, or in the past 12 months was, a client of Canaccord Genuity or its affiliated companies. During this period, Canaccord Genuity or its affiliated companies provided investment banking services to Atara Biotherapeutics.

In the past 12 months, Canaccord Genuity or its affiliated companies have received compensation for Corporate Finance/Investment Banking services from Atara Biotherapeutics .

In the past 12 months, Canaccord Genuity or any of its affiliated companies have been lead manager, co-lead manager or co-manager of a public offering of securities of Atara Biotherapeutics or any publicly disclosed offer of securities of Atara Biotherapeutics or in any related derivatives.

Canaccord Genuity or one or more of its affiliated companies is a market maker or liquidity provider in the securities of Atara Biotherapeutics or in any related derivatives.

Canaccord Genuity or one or more of its affiliated companies intend to seek or expect to receive compensation for Corporate Finance/ Investment Banking services from Atara Biotherapeutics in the next six months.

The primary analyst, a member of primary analyst's household, or any individual directly involved in the preparation of this research, has a long position in the shares or derivatives, or has any other financial interest in Atara Biotherapeutics, the value of which increases as the value of the underlying equity increases.

Atara Biotherapeutics Rating History as of 10/21/2015



Online Disclosures

Up-to-date disclosures may be obtained at the following website (provided as a hyperlink if this report is being read electronically) http://disclosures.canaccordgenuity.com/EN/Pages/default.aspx; or by sending a request to Canaccord Genuity Corp. Research, Attn: Disclosures, P.O. Box 10337 Pacific Centre, 2200-609 Granville Street, Vancouver, BC, Canada V7Y 1H2; or by sending a request by email to disclosures@canaccordgenuity.com. The reader may also obtain a copy of Canaccord Genuity's policies and procedures regarding the dissemination of research by following the steps outlined above.

General Disclosures

"Canaccord Genuity" is the business name used by certain wholly owned subsidiaries of Canaccord Genuity Group Inc., including Canaccord Genuity Inc., Canaccord Genuity Limited, Canaccord Genuity Corp., and Canaccord Genuity (Australia) Limited, an affiliated company that is 50%-owned by Canaccord Genuity Group Inc.

The authoring analysts who are responsible for the preparation of this research are employed by Canaccord Genuity Corp. a Canadian broker-dealer with principal offices located in Vancouver, Calgary, Toronto, Montreal, or Canaccord Genuity Inc., a US broker-dealer with principal offices located in New York, Boston, San Francisco and Houston, or Canaccord Genuity Limited., a UK broker-dealer with principal offices located in London (UK) and Dublin (Ireland), or Canaccord Genuity (Australia) Limited, an Australian broker-dealer with principal offices located in Sydney and Melbourne.

The authoring analysts who are responsible for the preparation of this research have received (or will receive) compensation based upon (among other factors) the Corporate Finance/Investment Banking revenues and general profits of Canaccord Genuity. However, such authoring analysts have not received, and will not receive, compensation that is directly based upon or linked to one or more specific Corporate Finance/Investment Banking activities, or to recommendations contained in the research.

Canaccord Genuity and its affiliated companies may have a Corporate Finance/Investment Banking or other relationship with the issuer that is the subject of this research and may trade in any of the designated investments mentioned herein either for their own account or the accounts of their customers, in good faith or in the normal course of market making. Accordingly, Canaccord Genuity or their affiliated companies, principals or employees (other than the authoring analyst(s) who prepared this research) may at any time have a long or short position in any such designated investments, related designated investments or in options, futures or other derivative instruments based thereon.

Some regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of research. This research has been prepared in accordance with Canaccord Genuity's policy on managing conflicts of interest, and information barriers or firewalls have been used where appropriate. Canaccord Genuity's policy is available upon request.

The information contained in this research has been compiled by Canaccord Genuity from sources believed to be reliable, but (with the exception of the information about Canaccord Genuity) no representation or warranty, express or implied, is made by Canaccord Genuity, its affiliated companies or any other person as to its fairness, accuracy, completeness or correctness. Canaccord Genuity has not independently verified the facts, assumptions, and estimates contained herein. All estimates, opinions and other information contained in this research constitute Canaccord Genuity's judgement as of the date of this research, are subject to change without notice and are provided in good faith but without legal responsibility or liability.

Canaccord Genuity's salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients and our proprietary trading desk that reflect opinions that are contrary to the opinions expressed in this research. Canaccord Genuity's affiliates, principal trading desk, and investing businesses may make investment decisions that are inconsistent with the recommendations or views expressed in this research.

This research is provided for information purposes only and does not constitute an offer or solicitation to buy or sell any designated investments discussed herein in any jurisdiction where such offer or solicitation would be prohibited. As a result, the designated investments discussed in this research may not be eligible for sale in some jurisdictions. This research is not, and under no circumstances should be construed as, a solicitation to act as a securities broker or dealer in any jurisdiction by any person or company that is not legally permitted to carry on the business of a securities broker or dealer in that jurisdiction. This material is prepared for general circulation to clients and does not have regard to the investment objectives, financial situation or particular needs of any particular person. Investors should obtain advice based on their own individual circumstances before making an investment decision. To the fullest extent permitted by law, none of Canaccord Genuity, its affiliated companies or any other person accepts any liability whatsoever for any direct or consequential loss arising from or relating to any use of the information contained in this research.

For Canadian Residents:

This research has been approved by Canaccord Genuity Corp., which accepts sole responsibility for this research and its dissemination in Canada. Canaccord Genuity Corp. is registered and regulated by the Investment Industry Regulatory Organization of Canada (IIROC) and is a Member of the Canadian Investor Protection Fund. Canadian clients wishing to effect transactions in any designated investment discussed should do so through a qualified salesperson of Canaccord Genuity Corp. in their particular province or territory.

For United States Residents:

Canaccord Genuity Inc., a US registered broker-dealer, accepts responsibility for this research and its dissemination in the United States. This research is intended for distribution in the United States only to certain US institutional investors. US clients wishing to effect transactions in any designated investment discussed should do so through a qualified salesperson of Canaccord Genuity Inc. Analysts employed outside the US, as specifically indicated elsewhere in this report, are not registered as research analysts with FINRA. These analysts may not be associated persons of Canaccord Genuity Inc. and therefore may not be subject to the NASD Rule 2711 and NYSE Rule 472 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

For United Kingdom and European Residents:

This research is distributed in the United Kingdom and elsewhere Europe, as third party research by Canaccord Genuity Limited, which is authorized and regulated by the Financial Conduct Authority. This research is for distribution only to persons who are Eligible Counterparties or Professional Clients only and is exempt from the general restrictions in section 21 of the Financial Services and Markets Act 2000 on the communication of invitations or inducements to engage in investment activity on the grounds that it is being distributed in the United Kingdom only to persons of a kind described in Article 19(5) (Investment Professionals) and 49(2) (High Net Worth companies, unincorporated associations etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended). It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons. This material is not for distribution in the United Kingdom or elsewhere in Europe to retail clients, as defined under the rules of the Financial Conduct Authority.

For Jersey, Guernsey and Isle of Man Residents:

This research is sent to you by Canaccord Genuity Wealth (International) Limited (CGWI) for information purposes and is not to be construed as a solicitation or an offer to purchase or sell investments or related financial instruments. This research has been produced by an affiliate of CGWI for circulation to its institutional clients and also CGWI. Its contents have been approved by CGWI and we are providing it to you on the basis that we believe it to be of interest to you. This statement should be read in conjunction with your client agreement, CGWI's current terms of business and the other disclosures and disclaimers contained within this research. If you are in any doubt, you should consult your financial adviser.

CGWI is licensed and regulated by the Guernsey Financial Services Commission, the Jersey Financial Services Commission and the Isle of Man Financial Supervision Commission. CGWI is registered in Guernsey and is a wholly owned subsidiary of Canaccord Genuity Group Inc.

For Australian Residents:

This research is distributed in Australia by Canaccord Genuity (Australia) Limited ABN 19 075 071 466 holder of AFS Licence No 234666. To the extent that this research contains any advice, this is limited to general advice only. Recipients should take into account their own personal circumstances before making an investment decision. Clients wishing to effect any transactions in any financial products discussed in the research should do so through a qualified representative of Canaccord Genuity (Australia) Limited. Canaccord Genuity Wealth Management is a division of Canaccord Genuity (Australia) Limited.

For Singapore Residents:

This research is distributed pursuant to 32C of the Financial Advisers under an arrangement between each of the Canaccord Genuity entities that publish research and Canaccord Genuity Singapore Pte. Ltd who is an exempt financial adviser under section 23(1)(d) of the Financial Advisers Act. This research is only intended for persons who fall within the definition of accredited investor, expert investor or institutional investor as defined under section 4A of the Securities and Futures Act. It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons. Recipients of this report can contact Canaccord Genuity Singapore Pte. Ltd. (Contact Tel: +65 6854 6150) in respect of any matters arising from, or in connection with, the research.

For Hong Kong Residents:

This research is distributed in Hong Kong by Canaccord Genuity (Hong Kong) Limited which is licensed by the Securities and Futures Commission. This research is only intended for persons who fall within the definition of professional investor as defined in the Securities and Futures Ordinance. It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons. Recipients of this report can contact Canaccord Genuity (Hong Kong) Limited. (Contact Tel: +852 3919 2561) in respect of any matters arising from, or in connection with, this research.

Additional information is available on request.